Hematologic Malignancy
Pipeline by Development Stage
Competitive Landscape
8 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Clinical Trials (10)
Total enrollment: 235 patients across 10 trials
An Extension Study for Patients Previously Enrolled in Studies With Pelabresib
Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies
MPH966 for Prevention of Graft-versus-host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
A Clinical Trial of TQB3909 Tablets Combined With TQB3702 Tablets in Patients With Hematologic Malignancy
A Phase I Study of BC3402 as a Single Agent in Patients With MDS and CMML
Tolerability and Pharmacokinetics Study of TQB3702 Tablets in Hematologic Tumor Subjects
A Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351
A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Therapies
Symptom Identification and Management in Patients With Hematological Malignancy During Follow-up Care